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Abstract
Background: Mild traumatic brain injury (mTBI) secondary to blast exposure is the most common battlefield injury in
Southwest Asia. There has been little prospective work in the combat setting to test the efficacy of new countermeasures.
The goal of this study was to compare the efficacy of N-acetyl cysteine (NAC) versus placebo on the symptoms associated
with blast exposure mTBI in a combat setting.
Methods: This study was a randomized double blind, placebo-controlled study that was conducted on active duty service
members at a forward deployed field hospital in Iraq. All symptomatic U.S. service members who were exposed to
significant ordnance blast and who met the criteria for mTBI were offered participation in the study and 81 individuals
agreed to participate. Individuals underwent a baseline evaluation and then were randomly assigned to receive either N-
acetyl cysteine (NAC) or placebo for seven days. Each subject was re-evaluated at 3 and 7 days. Outcome measures were the
presence of the following sequelae of mTBI: dizziness, hearing loss, headache, memory loss, sleep disturbances, and
neurocognitive dysfunction. The resolution of these symptoms seven days after the blast exposure was the main outcome
measure in this study. Logistic regression on the outcome of ‘no day 7 symptoms’ indicated that NAC treatment was
significantly better than placebo (OR= 3.6, p = 0.006). Secondary analysis revealed subjects receiving NAC within 24 hours of
blast had an 86% chance of symptom resolution with no reported side effects versus 42% for those seen early who received
placebo.
Conclusion: This study, conducted in an active theatre of war, demonstrates that NAC, a safe pharmaceutical
countermeasure, has beneficial effects on the severity and resolution of sequelae of blast induced mTBI. This is the first
demonstration of an effective short term countermeasure for mTBI. Further work on long term outcomes and the potential
use of NAC in civilian mTBI is warranted.
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Introduction
Mild traumatic brain injury (mTBI) is the most common injury
seen in the current conflicts in Iraq and Afghanistan and an
increasingly common injury in modern society. An estimated
19.5–22.8% of all returning deployed troops suffer from mTBI [1].
The most common cause of mTBI is blast exposure from
improvised explosive devices (IEDs) or other explosive ordinances.
Over the last three decades the mechanisms, characteristics,
diagnostic schemes, and treatment strategies for blunt head
trauma have been studied extensively. Unfortunately, many of
the lessons learned from blunt head trauma cannot be applied
automatically to blast injured subjects [2].
Disentangling the neurological features of mTBI from PTSD is
important for improving diagnosis and treatment of low-level blast
injuries [3]. Many previous studies were conducted well after the
actual blast injury and focused on the role of mTBI as a precursor
of PTSD [1,4]. Diagnosis of mTBI requires a documented
traumatic event, with a transient loss or alteration of conscious-
ness, accompanied by at least one of a list of neurologic,
neurotologic, or cognitive symptoms [5]. One highly prevalent
symptom is dizziness, a subjective marker of balance dysfunction.
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N-acetylcysteine (NAC) is a logical choice for a field-based
clinical trial. NAC is the active agent in Mucomyst, an FDA
approved medication with a forty-year safety history. NAC is an
effective neuroprotective agent in animal ischemia-reperfusion
cerebral stroke models [6,7,8], a rodent closed head trauma model
[9], a sensory nerve axotomy model [10] and inner ear neuronal
death after noise exposure [11,12]. Although these neuroprotec-
tive effects of NAC appear to be mediated by both antioxidant and
anti-inflammatory effects [7,8,13,14,15], NAC also acts indirectly
at metabotropic glutamate receptors to counteract cocaine-
induced disruption of nucleus accumbens [16]. Further, oral
NAC and placebo preparations have been utilized on over 1000
Marines and Sailors in on-going approved clinical investigations to
test protection from noise-induced hearing loss. Finally, NAC has
limited capability to cross the normal blood-brain barrier [13],
which suggests that it can preferentially enter tissue at sites of post-
traumatic barrier disruption.
This protocol administered a loading dose of NAC to exposed
U.S. Service members within 0–72 hours after blast exposure and
followed a set of subjective and objective outcome measures of
mTBI. The addition of NAC to standard treatment produced a
much higher rate of symptom resolution than placebo at seven
treatment days.
Materials and Methods
Overview
The study is the first double blind, placebo controlled study
examining mTBI to take place during active combat. It was
subject to design constraints because the participants were active
duty personnel who never departed from an active combat zone.
Diagnosis and treatment of mTBI were delivered by medical
personnel in a medical facility within that active combat zone.
Operational manpower needs and military policy precluded
follow-up beyond the initial seven day treatment period. Enroll-
ment in the study ended with the conclusion of combat operations
in Western Iraq. A flow diagram for the study is shown in Figure 1.
Ethics
The protocol was approved by the Joint Theatre Trauma and
Research Office in Baghdad, Iraq and the theatre Institutional
Review Board (IRB) at Brooke Army Medical Center.
Detailed Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The study was conducted at Al Taqaddum Level II
Medical Facility (TQ) in Iraq. US Military Service members
exposed to a significant blast in the Al Anbar province of Iraq were
evaluated at TQ as rapidly as feasible (given operational and
weather concerns). The October 2007 Joint Service Surgeon
General and DoD Health Affairs criteria were utilized to diagnose
mTBI [5]. Briefly, this definition specifies that there is an
exposure, a brief alteration of consciousness, and then manifesta-
tion of any one of a number of mTBI symptoms. Exposure was
defined as feeling a blast wave or being in a vehicle that was
damaged by a blast wave. Alteration of consciousness required a
report by another individual on the scene. Balance dysfunction,
confusion, headache, sensorineural hearing loss, impaired memory
and sleep disturbances were considered as mTBI symptoms.
Individuals with moderate to severe TBI, significant orthopedic
injuries, or those requiring computerized tomography scans,
evacuation from theatre, or emergent surgeries were excluded
from this study.
All subjects underwent a comprehensive history and physical
exam by the Principal Investigator (PI). A finding of balance
dysfunction required subjective dizziness, an abnormal head thrust
test (abnormal eye motion after quick turning of the subjects head
by the investigator [17]), an abnormal Romberg/tandem Rom-
berg test (excessive swaying or falling while attempting to stand still
with eyes closed and arms extended [18]), and an abnormal
dynamic gait index (DGI) score (a dedicated set of walking tasks
scored by the PI [19]) of ,22. Criteria for resolution of balance
dysfunction were no subjective dizziness, normal head thrust and
Romberg tests, and a normal DGI. Audiometric testing identified
hearing loss and its resolution. Confusion, headache, sleep
disturbances, and impaired memory were based upon self-reports;
resolution of these symptoms required a report that ‘‘I feel as good
as before the blast.’’ Sleep disorders were difficult to assess because
many subjects were sleep deprived upon arrival; they were
diagnosed when clinical judgment indicated that initial exhaustion
was eliminated.
All subjects diagnosed with mTBI were given standard
treatment for signs and symptoms as needed, which was identical
to treatment administered for mTBI in US military and civilian
hospitals. Treatment included an individualized exercise program,
symptomatic headache medications (non-narcotic medicine such
as topiramate, sumatriptin, and ibuprofen to treat associated
symptoms), low level of activity with proper rest, and controlled
mental stimulation. All subjects were also informed about the
study and offered an opportunity to participate. All individuals
were advised that participation was voluntary and would have no
impact on their ability to receive care or on their ability to receive
standard of care for their injury. All individuals who desired to
consider participating were given an informed consent form to
read and allowed ample opportunity to ask questions. Those
agreeing to participate completed the IRB approved informed
consent document. All participants received a pre-randomized
bottle containing 500 mg tablets of either NAC or placebo,
prepared by the pharmacy of a major United States Military
Medical Center. Assignment was based solely on order of
accession into the study. Simple randomization was utilized to
create an assignment list (randomization schedule) for subjects to
be assigned to either the Placebo or NAC group as no interim
analyses were to be conducted and this method assures that each
treatment assignment is completely unpredictable [20]. The
randomization schedule was created prior to subject accrual and
resulted in a 49?4% to 50?6% split in subjects between the two
groups. Participants, providers, and evaluators were all blinded to
which treatment group each subject was assigned.
The 4 gram loading dose was witnessed and then bottles were
name labeled and given to the subject’s corpsman, medic or a
nurse (for subjects remaining at TQ). Beginning 18–24 hours after
the loading dose, subjects were given 4 grams daily (in two divided
doses of 2 gm morning and night) for 4 days. The dose was then
reduced to 3 gm daily [in two divided doses of 1.5 gm morning
and night]. Every dose was witnessed by a corpsman, medic,
nurse, or doctor.
The Controlled Oral Word Association Test (COWA) [21],
animal naming (AN), and timed Trail Making Tests (TMT) A and
B [22,23,24,25] were administered as neuropsychological tests of
executive function. Normative TMT data were estimated from
published age-normed data [26], assuming an equal mixture of
18–24 and 25–34 year old groups. The initial clinical assessment,
history, physical, DGI, hearing, and neuropsychology tests were
repeated at three and seven days after enrollment.
The study was designed originally to examine the effects of
NAC versus placebo in subjects also receiving standard treatment
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(measured exercise program and non-narcotic headache medi-
cines). Because availability of transportation in the combat zone
affected a patient’s arrival time at TQ, we also examined
secondarily the impact of early (within 24 hours) versus delayed
(26–72 hours after injury) diagnosis and treatment on outcomes.
Time of arrival at TQ was based purely on distance of the injury
from TQ and the safety and availability of transportation back to
TQ. While it is impossible to control for all confounders between
the early and late group, it should be noted that individuals in both
groups came from the same sets of combat units, were doing the
same duty, and were living under the same conditions. The
primary endpoint was the percentage of subjects free of all
symptoms of mild TBI on D7 where D7 was defined 7 days since
the loading dose of medication was given. It was assumed that
80% of subjects in the placebo arm of the study would still have at
least one symptom on day 7. The study was sized to determine if
NAC was able to reduce that 80% to 50%, hence only 50% of
subjects would still have a symptom of mild TBI on day 7, with a
95% level of confidence, 80% power, and a 1:1 ratio of control to
experimental subjects. Based upon these criterion, 38 subjects were
required in each arm of the study [27]. Secondary endpoints were
balance dysfunction resolution, absence of headache, confusion,
memory problems, abnormal sleep, trail making A, trail making B,
controlled oral word association (COWA), and animal naming
(AN) all on day 7, as well as the percentage of subjects free of all
symptoms of mild TBI three days post initial treatment.
Student t-tests were utilized to determine differences between
groups for age, distance from blast and number of blast exposures
at time of assignment for treatment. Pooled variance determined
significance unless group variances were significantly different, in
which case Satterthwaite’s method was used. MLR and Least
Significant Differences (LSD) tests were used for multiple
comparisons. Fisher’s exact test was used to test group differences
for categorical variables of sex and job title.
For the primary analysis, unadjusted logistic regression was used
to model the effect of NAC on resolution of symptoms D7. For
secondary analyses, multivariate logistic regression modeled the
effects of NAC, early treatment, number of previous blast
occurrences, age, distance from blast, as well as all two-way
interactions, on resolution of symptoms on D7. Parsimonious
models [28] were constructed utilizing a backward elimination
strategy with a significance level to stay of a=0?05. In a similar
manner, multivariate linear regression modeled predictors of the
number of D7 symptoms. Parallel analyses of day 3 data revealed
no significant effects.
Results
General subject characteristics
Eighty-one subjects participated in the study (eighty males and
one female). The age range was 18–43 years of age with a median
age of 22 years. The subject demographic data (Table 1) did not
differ between the NAC and the placebo groups, between subjects
Figure 1. Consort Flow Diagram.
doi:10.1371/journal.pone.0054163.g001
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treated early (#24 hours) or late (26–72 hours) after injury, or
between any of the four treatment groups defined by combinations
of these factors. The groups did not differ with respect to other
medicines being utilized. Neither alcohol nor drug abuse were
factors because the study was conducted in a controlled combat
setting. Theatre guidelines prohibited a detailed documentation or
tracking of those who declined participation but over 1/3 of those
seen declined to participate in the trial. No participant suffered
unintended effects, side effects, or harm. In particular, no GI upset
was reported.
All subjects in the study had objective clinical evidence of
balance dysfunction. Table 2 summarizes the distribution of
additional mTBI symptoms. Only one subject had an isolated
finding of balance dysfunction. Hearing loss, headache and
confusion were the next most prevalent features.
Symptom emergence during the study
The prevalence of mTBI symptoms varied with the latency
between blast exposure and examination. Hearing loss emerged on
subsequent study days in 3 subjects, headache developed in 8
subjects, memory problems in 2 subjects and abnormal sleep in 10
subjects. Symptoms persisting at D7 are shown in Table 3.
Treatment effects
The NAC group was significantly more likely to have symptom
resolution D7 (OR=3.60, p = 0.0062, R2= 0.37). In secondary
analyses, both NAC treatment and early treatment initiation
contributed independently to symptom resolution (Figure 2, left
panels). There were independent main effects of both NAC
treatment (F1, 78 = 10?28, p,0.01) and treatment initiation time
(F1, 78 = 10?91, p,0.01) on the number of D7 symptoms
(R2= 0.21). The early treatment group given NAC had the fewest
D7 symptoms (p,0?01, R2= 0.24 re: each other group by LSD
tests). The early treatment group without NAC showed fewer
symptoms than the late treatment group without NAC (p,0.05).
The late treatment group given NAC showed an intermediate
number of symptoms that did not differ significantly from either
early or late treatment groups without NAC There were no
significant treatment group differences in the total number of
symptoms upon entry (R2 = 0.03) or on treatment day 3
(R2= 0.04).
Logistic regression on the outcome of ‘no D7 symptoms’
confirmed that NAC treatment was significantly better than
placebo (p,0.005) and early intervention was significantly better
than later intervention (p,0.005, max-rescaled R2= 0.37)). The
odds of complete symptom resolution for Group B (early treatment
with NAC) were greater than the other groups (Tables 4 and 5,
p,0.001). Parsimonious logistic regression models for balance
dysfunction resolution and the absence of headache on day seven
also showed significant effects for NAC and early treatment
initiation (p,0.05), with no significant effects of covariates or
interactions.
Confusion resolved markedly after early treatment; 59/60
subjects treated early had no confusion D7, compared with only
14/21 subjects treated later (exact test, p,0.001). The parsimo-
nious logistic regression model showed that D7 confusion was
predicted by both the time of treatment (p,0.05) and the distance
from the blast (p,0.05). No significant effects emerged in the
parsimonious logistic regression models for hearing loss, memory
problems and abnormal sleep. Despite the low prevalence of
abnormal sleep in this series, it was significantly less likely (exact
test, p = 0.029) in the NAC treated subject population on day
seven (1/41) than in the placebo treated subjects (7/40).
Neuropsychological treatment effects
Results on entry were significantly poorer than published
normative Trail making Test A and B (TMTA and TMTB) data
for subjects who were in the age ranges of 18–34 years [26]
(Table 6, z-tests, p,0.001). Controlled oral word association
(COWA) and animal naming (AN) were within normal limits.
NAC administration restored normal TMT performance within
7 days after blast-induced mild traumatic brain injury (mTBI)
(Table 7). The D7 MLR showed TMTA (F(1,74) = 6.64, p,0.05)
and TMTB (F(1,74) = 4.866, p,0.05) scores were improved
significantly by NAC treatment and scores for the NAC treated
groups were equivalent to age-based norms. The D7 TMT scores
for groups that did not receive NAC remained impaired. The D7
COWA and AN results showed no group differences (Tables 8 and
9).
The D7 TMT performance paralleled the resolution of mTBI
symptoms. Times were significantly shorter in symptom-free
subjects (Bonferroni-adjusted t-tests, p,0.05). Subjects who were
symptom free on D7 had normal TMTA and TMTB times, while
the symptomatic subjects had prolonged times.
TM perforation and outcomes. TM perforation is a
common combat-related blast injury [29,30,31,32] that may
indicate the magnitude of shock wave exposure [30,33,34] and
be a proxy for blast over-pressure intensity [28,29]. The number of
symptoms and TMT test results at time of entry (day 0) were
unaffected by TM status. TM perforation and NAC treatment
status were both significant predictors of the number of day 3
symptoms (ANOVA, F(1,78) = 33.51, p,0.001 and F(1,78) = 4.64,
Table 1. Study Group Characteristics.
Continuous
Covariates Treatment Before 24 Hours Treatment After (26–72 Hours)
Group A: -NAC Control(n= 31) Group B: +NAC (n=29) Group C: -NAC Control (n= 9) Group D: +NAC (n=12)
Mean Std Dev Mean Std Dev Mean Std Dev Mean Std Dev
Age 23.58 4.16 24.92 6.52 25.42 6.19 27.68 6.96
Distance from blast
(feet){
17.42 7.40 16.79 5.18 14.67 2.69 15.83 4.69
Number of Blast
Exposures (inclusive)
2.23 3.60 1.45 1.21 1.89 1.69 6.58 8.31{
{include vehicle dimensions (74/81 participants) and IED distance.
{Greater variance reflects the random inclusion of the two oldest individuals in the study population.
doi:10.1371/journal.pone.0054163.t001
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p= 0.034, respectively). For the early treatment initiation group,
the reduction of D7 symptoms by NAC treatment was indepen-
dent of TM status (ANOVA, F (1, 56) = 12.19, p= 0.001). NAC
treatment also produced significantly better resolution (no D7
symptoms) than placebo (logistic regression, p,0.005).
Discussion
This is the first prospective, double-blinded, placebo-controlled
randomized study to focus on the acute treatment of combat blast-
related mTBI in a forward war zone. Supplementation of standard
therapy with oral NAC had a significant impact on neuropsycho-
logical test results, number of mTBI symptoms, and complete
symptom resolution by day seven of treatment when compared to
placebo. Moreover, the pill form of NAC, the active ingredient in
the FDA approved medication ‘‘Mucomyst’’, produced no side
effects in blast mTBI subjects. Although the study was powered
only to examine the effects of NAC, there was a statistically
significant secondary finding that standard treatment initiation
Table 2. Distribution of mTBI Symptoms Co-morbid with Balance Dysfunction: Entry to Study.
Number of Symptoms Hearing loss Headache Confusion Memory Problem Sleep Abnormal Number of Subjects
1 2 2 2 2 2 1
2 + 2 2 2 2 6
2 + 2 2 2 6
2 + 2 2 2 6
3 2 + 2 + 2 7
2 + + 2 2 6
+ 2 2 2 + 1
+ + 2 2 2 8
+ 2 2 + 2 2
+ 2 + 2 2 13
4 + 2 + + 2 1
+ + + 2 2 17
+ + 2 + 2 7
+ + 2 2 + 1
5 + + + 2 + 1
Subjects Symptomatic 57 53 42 17 3 81
doi:10.1371/journal.pone.0054163.t002
Table 3. Unresolved mTBI Symptom Patterns on Treatment Day 7.
Number of Symptoms Balance dysfunction Hearing loss Headache Confusion Memory ProblemSleep Abnormal
Number of
Subjects
1 2 + 2 2 2 2 3
2 2 + 2 2 2 4
2 2 2 + 2 2 3
+ 2 2 2 2 2 4
2 2 2 + 2 2 + 1
2 + + 2 2 2 2
2 2 + + 2 2 1
+ 2 2 2 2 + 3
+ + 2 2 2 2 3
+ 2 + 2 2 2 6
3 2 + + + 2 2 1
+ + + 2 2 2 3
+ 2 + 2 2 + 2
+ 2 + + 2 2 2
4 + 2 + + 2 + 1
5 + + + 2 + + 1
Subjects Symptomatic 25 13 24 8 1 8 40
doi:10.1371/journal.pone.0054163.t003
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within 24 hours had an independent benefit on neurological but
not on neuropsychological outcome measures (TMT). A possible
explanation for this difference is that the outcome measures assess
the status of different neuronal circuitry components. The additive
effects of NAC and early treatment produced 86% mTBI
symptom resolution within seven days. Factors such as number
of previous blast exposures, age and distance from the blast did not
influence treatment outcomes significantly.
Headache and balance dysfunction are major clinical issues that
arise acutely after blast exposure, impede return to duty, and can
Figure 2. The number of symptoms for four groups of patients. The upper left panel shows results for all patients in the study. The upper
right graph illustrates the impact of tympanic membrane perforations in the patients seen within 24 hours of blast exposure The distribution of the
data on day 7 are shown for each group in the lower graphs, with a pie chart to indicate the percentage with no residual symptoms.
doi:10.1371/journal.pone.0054163.g002
Table 4. Treatment Effects: Day 7 Symptoms.
No Symptoms- Day 7
No Symptoms (Excluding Residual hearing loss-Day
7
Timing of
Treatment Treatment n Odds Ratio*
Max Rescaled
R2 Pr.ChiSq Odds Ratio*
Max Rescaled
R2 Pr.ChiSq
After 24 hours Placebo 9 1 (reference) 0.38 0.0002 1 (reference) 0.34 0.0005
After 24 hours NAC 12 1.60 (0.12, 20.99) 2.67 (0.23, 31.07)
Before 24 hours Placebo 31 5.05 (0.56, 45.64) 5.78 (0.64, 52.03)
Before 24 hours NAC 29 38.40 (3.88, 379.68) 38.40 (3.88, 379.68)
*95% Confidence Interval.
doi:10.1371/journal.pone.0054163.t004
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persist chronically [1,4,35]. Because they seriously impair perfor-
mance in a combat environment, the initiation of standard
treatment with oral NAC within 24 hours of mTBI is likely to have
a definitive impact on battlefield end-strength and the readiness of
troops in theater.
Performance on TMT neuropsychological tests was impacted
significantly by blast mTBI and ameliorated by NAC administra-
tion. The initial test times were prolonged significantly at
enrollment. NAC administration within 72 hours of injury
produced normal D7 TMT times, but performance remained
abnormal for subject groups that received only standard therapy.
Because all subjects were tested on the same schedule and the
reliability of repeated TRAIL making tests [25] is well document-
ed, test-retest effects are not a confounding factor. Hence, TMTs
are useful for documenting and monitoring cognitive status
changes in acute blast mTBI.
The efficacy of NAC in early treatment of blast mTBI is
consistent with its efficacy as a neuroprotective agent in ischemia-
reperfusion cerebral stroke [6,7,8], closed head trauma [9],
sensory nerve axotomy [10] and in the prevention of mitochon-
drial damage and loss of dendritic spines in hippocampal neurons
[36] in animal models of closed head trauma and ischemia-
reperfusion brain injury. A single, low level shock wave exposure
to rodents can produce persistent biochemical changes in the
hippocampus and cerebral cortex, accompanied by apoptotic cell
death [37,38,39]. Even relatively low exposures produce very
small parenchymal and subarachoid hemorrhages in 30–40% of
exposed animals [40]. These findings suggest that vascular primary
injury contributes to symptoms of mTBI, with slower development
of neuronal damage [41]. Post-treatment with NAC has afforded
protection against neuronal death in animal models. These
neuroprotective effects reflect known antioxidant and anti-
inflammatory effects [7,8,13,14,15,36]. The cellular bases for
memory and regulation of motivation properties within the
nucleus accumbens may be improved by NAC activating neuronal
cysteine-glutamate exchange and indirect effects on mGluR2/3
and mGluR5 [16] transmission. Finally, enhanced local bioavail-
ability of NAC may be a natural consequence of vascular
disruption in mTBI. Because NAC has limited capability to cross
the normal blood-brain barrier [13], increased local brain
permeability during vascular remodeling [42] may facilitate
selective delivery to affected sites. A delayed opening of the
blood-brain barrier from neuroinflammatory responses [42,43],
could create longer-term therapeutic opportunities.
Early symptomatic treatment initiation produced improvement
that was statistically independent of effects of NAC treatment. The
early and late subjects came from the same set of combat units
with a shared history of living environment, combat exposure and
similar clinical presentations. Although we believe that the time of
enrollment was determined only by distance from TQ and
availability of transport, it is impossible to know if there were
unknown confounders between the two groups. However, we
believe that the improvement seen in early subjects can be
attributed to the concurrent standard symptomatic medical
treatment and balance rehabilitation exercises begun earlier in
the early treatment group. Exercise, in particular, can have
neuroprotective pharmacomimetic effects on structures such as the
hippocampus, possibly mediated by trophic factors [44].
Clinical trials in an active combat theater are subject to outside
factors for ‘‘early termination’’ that do not arise in standard
clinical environments. For this study, the opportunity for subject
enrollment ended when combat operations terminated in this part
of Iraq, prior to reaching the pre-determined number of enrollees
for the trial. Because the available data were powered sufficiently
to test the effects of NAC, we proceeded with analysis after all
patients completed the protocol. The enthusiasm about the large
treatment effect must be tempered by a recent review of the
Cochran database [45], showing that studies with relatively small
Table 5. Treatment Effects: Day 7 Symptoms.
No Balance Dysfunction - Day 7 No Headache -Day 7
Timing of
Treatment Treatment n Odds Ratio*
Max Rescaled
R2 Pr.ChiSq Odds Ratio*
Max Rescaled
R2 Pr.ChiSq
After 24 hours Placebo 9 1 (reference) 0.21 0.0185 1 (reference) 0.25 0.0117
After 24 hours NAC 12 4.00 (0.64, 25.02) 2.80 (0.46, 16.93)
Before 24 hours Placebo 31 3.17 (0.66, 15.12) 3.64 (0.76, 17.46)
Before 24 hours NAC 29 17.33 (2.78, 108.06) 27.00 (3.67, 198.69)
*95% Confidence Interval.
doi:10.1371/journal.pone.0054163.t005
Table 6. Neuropsychological Tests: TMT at Study Entry.
Trail Making A (seconds) – At entry to study Trail Making B (seconds) – At entry to Study
Timing of Treatment Treatment n
Mean (Standard
Deviation) R2 Pr.F
Mean (Standard
Deviation) R2 Pr.F
After 24 hours Placebo 9 38.4 (19.9)** 0.04 0.4243 62.2 (24.4)** 0.01 0.8941
After 24 hours NAC 12 37.4 (20.7)** 70.3 (45.9)**
Before 24 hours Placebo 30 31.4 (11.3)** 66.5 (20.8)**
Before 24 hours NAC 27 32.4 (9.2)** 69.0 (21.7)**
doi:10.1371/journal.pone.0054163.t006
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patient numbers and large odds ratios often show smaller odds
ratios when the study is repeated. In this regard, we do note that
the lower bounds of the 95% confidence intervals for early NAC
treatment are reasonably large. It also should be noted that
although we were able to draw some statistical conclusions the
study was not powered to look at early vs. late treatment which
argues for caution in interpreting that data.
One must be cautious to assert the therapeutic implications of
NAC treatment for TBI within the limited scope of this study.
While the results are very promising, the study was limited to
evaluating a relatively small but representative sample of combat
troops with acute mild head trauma and other minor injuries over
one week of treatment. Some additional caveats are also inherent
in the far-front battlefield environment. For example, study
participants came from the same set of combat units with similar
environmental exposure histories, living conditions (including the
same forward operating bases), training, missions, and combat
environments; combat personnel are predominantly males in their
twenties. Therefore, it is prudent to consider several caveats for
our findings. The study results do not imply any benefit for
moderate or severe head trauma with significant surgical injuries.
Because only one female was enrolled, the study may not
generalize to all females. Although the study endpoint was only
D7 there is some evidence to suggest that these effects may be long
lasting. Tweedie, et al [46] have shown that mTBI triggers
biochemical cascades within the first 24 hours which produce long
term sequelae. Their work suggests that it is important to interrupt
these cascades as early as possible. D7 resolution may indicate the
lack of significant apoptotic and inflammatory changes in both
grey and white matter. Nevertheless, the effects of treatment on
longer term outcomes will need to be the subject of further study in
a larger number of subjects.
The study can then, at least, be interpreted in a narrow fashion
as showing a benefit of using NAC and early intervention for blast
mTBI in an acute combat setting after mild blast exposure. The
study brings up the intriguing possibility that NAC may be useful
in other mTBI settings, but before this conclusion be reached
much more study in the area and using this agent is required.
Summary and Conclusions
We report the first double blinded placebo- controlled
randomized study of a pharmaceutical countermeasure for the
symptoms of blast-induced mTBI. All 81 subjects were seen within
72 hours of blast exposure by the same clinician-investigator at a
forward location in an active combat zone. All medications and
treatments were witnessed by a nurse, corpsman, or medic. The
outcomes demonstrate that supplementation with oral NAC had a
significant impact on neuropsychological test results, number of
mTBI symptoms, and complete symptom resolution by day seven
of treatment when compared to placebo. A secondary finding was
that standard treatment initiation within 24 hours had an
independent benefit on the neurological but not on neuropsycho-
logical outcome measures. Early treatment with NAC and
standard therapy administered by a provider with expertise in
mTBI care resulted in a seven day symptom resolution rate of 86%
as compared to 11% in those receiving the same standard care by
the same provider but who received placebo and began therapy
between 24–72 hours after blast exposure. Additionally it should
be noted that during this trial the pill form of NAC, the active
ingredient in the FDA approved medication Mucomyst, produced
no side effects in blast mTBI subjects. Mucomyst has an excellent
safety profile in over forty years of use in hospitals worldwide. As
such use of this medicine appears to be the first described
pharmaceutical countermeasure for mTBI. These results while
promising are still preliminary. This outcome needs to be
supported by other studies of NAC for this pathophysiology
examining neurosensory symptoms over a variety of time points
both acute and chronic. Additionally, these findings argue for
Table 7. Neuropsychological tests: TMT at Day 7.
Trail Making A (seconds) – Day 7 Trail Making B (seconds) – Day 7
Timing of Treatment Treatment n
Mean (Standard
Deviation) R2 Pr.F
Mean (Standard
Deviation) R2 Pr.F
After 24 hours Placebo 9 34.2 (18.3)** 0.09 0.0633 63.6 (16.3)** 0.07 0.1504
After 24 hours NAC 12 23.4 (4.9) 50.2 (15.9)
Before 24 hours Placebo 30 27.0 (12.0)* 56.2 (20.1)*
Before 24 hours NAC 27 23.5 (7.7) 49.1 (17.1)
*p,0.05 or **p,0.01 by z-test versus TMTA (23.767.8 seconds (S.D.)) or TMTB.
doi:10.1371/journal.pone.0054163.t007
Table 8. Neuropsychological Tests: COWA and Animal Naming at Study Entry.
COWA – At entry to study Animal Naming – At entry to Study
Timing of
Treatment Treatment n
Mean (Standard
Deviation) R2 Pr.F
Mean (Standard
Deviation) R2 Pr.F
After 24 hours Placebo 9 30.6 (8.0) 0.07 0.1245 17.4 (3.4) 0.02 0.7787
After 24 hours NAC 12 35.3 (8.3) 19.7 (6.5)
Before 24 hours Placebo 30 39.3 (11.2) 19.4 (6.1)
Before 24 hours NAC 27 35.3 (10.1) 19.9 (6.9)
doi:10.1371/journal.pone.0054163.t008
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investigations of this therapy for other causes of traumatic brain
injury.
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